Aetion Recognized as a Leader in CB Insights’ Synthetic Patient Data Market Analysis

Aetion has been named a Leader in CB Insights’ Synthetic Patient Data Market Analysis, earning the highest score of 9.8/10 among 15 evaluated companies. This recognition underscores Aetion’s role in advancing the synthetic patient data market through its scientifically rigorous solutions designed to address the complex challenges of privacy, security, and data access.

What Sets Aetion Apart

The CB Insights Execution, Strength, and Positioning (ESP) matrix evaluates companies based on their ability to meet market demands with innovative and impactful solutions. Aetion’s top score reflects its:

• Scientific Rigor: Delivering decision-grade synthetic data that is defensible through our comprehensive utility assessments.
• Versatility: Supporting diverse therapeutic areas and data types with robust data integration capabilities.
• Transparency: Promoting trust with clear methodologies and robust data selection processes.

“Since Aetion first expanded into synthetic patient data with the acquisition of the pioneering startup Replica Analytics in 2022, we have advanced the use of synthetic patient data as a vital tool for clinical research, treatment evaluation, and privacy risk assessment by enabling robust, decision-grade evidence generation,” said Kevin Riley, President of Aetion. “We wrote the book on synthetic data in healthcare and this recognition by CB Insights highlights the scientific foundation of Aetion’s platform and its ability to address the complex analytical needs of our clients.”

Elevating Synthetic Data with Aetion Generate

At the heart of Aetion’s leadership is Aetion® Generate, a purpose-built solution designed to transform synthetic patient data into actionable insights. By integrating cutting-edge technologies and scientific rigor, Aetion Generate overcomes privacy, security, and compliance challenges to unlock the full potential of real-world evidence (RWE).

Key capabilities of Aetion Generate include:

• AI-Powered Privacy Safeguards: Advanced algorithms assess and mitigate re-identification risks, ensuring compliance with global privacy standards like GDPR and HIPAA.
• Robust Synthetic Data: Synthetic datasets mirror real-world patterns while maintaining statistical fidelity, enabling secure and compliant research.
• Comprehensive De-Identification: Techniques like salted SHA-256 hashing, random ID generation, and suppression protect sensitive identifiers while preserving data utility.
• Transparent and Reproducible Workflows: Full auditability ensures defensible and reproducible insights for regulators and researchers.
• Seamless Integration with the Aetion Evidence Platform®: Synthetic datasets integrate effortlessly into workflows, enabling streamlined cross-functional collaboration.

Driving Impact Across Healthcare

Aetion Generate empowers organizations to achieve measurable outcomes:

• Accelerate Research: Streamlined workflows simplify data preparation, reducing timelines and expediting clinical trials.
• Enhance Cost Efficiency: By minimizing reliance on external vendors and optimizing in-house capabilities, organizations reduce data acquisition costs and improve ROI.
• Support Collaborative Research: Privacy-compliant synthetic data fosters secure, multi-institutional collaboration without compromising analytical utility.
• Drive Evidence-Based Decisions: High-quality synthetic data supports informed decision-making across clinical and commercial domains.

Transforming Research with Synthetic Patient Data

Aetion’s recognition by CB Insights underscores its commitment to redefining how healthcare organizations leverage synthetic patient data. With the advanced capabilities of Aetion Generate, organizations can navigate complex data privacy challenges, produce evidence-ready datasets, and accelerate impactful research.

Ready to elevate your research capabilities? Connect with us to learn how Aetion Generate can help your organization overcome data challenges and deliver meaningful results.